Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
European Journal of Cancer2009Vol. 45(11), pp. 1959–1968
Citations Over TimeTop 1% of 2009 papers
Suzanne George, Jean‐Yves Blay, Paolo G. Casali, Axel Le Cesne, Patricia Stephenson, Samuel E. DePrimo, Charles S. Harmon, Calvin Law, Jeffrey A. Morgan, Isabelle Ray‐Coquard, Vanessa Tassell, D. P. Cohen, George D. Demetri
Related Papers
- → Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports(2009)10 cited
- → Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma(2011)7 cited
- → Acute sunitinib neurotoxicity(2021)4 cited
- Guillain-Barré syndrome after treatment with sunitinib malate?(2008)
- → Development of sunitinib in the treatment of imatinib-resistant gastrointestinal stromal tumors(2011)